» Articles » PMID: 26017119

Brimonidine Reduces TGF-beta-induced Extracellular Matrix Synthesis in Human Tenon's Fibroblasts

Overview
Journal BMC Ophthalmol
Publisher Biomed Central
Specialty Ophthalmology
Date 2015 May 29
PMID 26017119
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Brimonidine is a highly selective α2 adrenergic agonist that has been widely used in anti-glaucoma eyedrops. The aim of this study was to investigate its putative anti-fibrotic role in the fibrosis caused by activated Tenon's fibroblasts.

Methods: Primary cultured human Tenon's fibroblasts were exposed to 2.0 ng/mL of transforming growth factor-β1 (TGF-β1) for up to 48 h. In the presence of various concentrations of brimonidine (from 0.0 to 10.0 μM), the expression levels of fibronectin, collagen types I and III, and β-actin were determined by Western immunoblots. The expression of phosphorylated SMAD2/3 (p-SMAD2/3) was then evaluated using immunofluorescence.

Results: TGF-β1 significantly increased the synthesis of fibronectin and collagens in human Tenon's fibroblasts; however brimonidine treatment distinctly attenuated the TGF-β1-induced production of extracellular matrix (ECM) proteins. TGF-β1 also changed the cellular morphology to be plump, while brimonidine treatment returned the cells to a spindle shape, similar to control fibroblasts. Regarding p-SMAD2/3, brimonidine treatment did not show any apparent changes in its expression.

Conclusions: Our data revealed that brimonidine reduces TGF-β-induced ECM synthesis in human Tenon's fibroblasts in vitro. This finding implies that topical administration of brimonidine may be helpful in reducing the fibrosis caused by the long-term use of topical anti-glaucoma medications.

Citing Articles

An α2-Adrenergic Agonist, Brimonidine, Beneficially Affects the TGF-β2-Treated Cellular Properties in an In Vitro Culture Model.

Watanabe M, Sato T, Tsugeno Y, Higashide M, Furuhashi M, Umetsu A Bioengineering (Basel). 2022; 9(7).

PMID: 35877361 PMC: 9312232. DOI: 10.3390/bioengineering9070310.


Elucidating the Therapeutic Potential of Cell-Penetrating Peptides in Human Tenon Fibroblast Cells.

Chatterjee A, Ansar S, Gopal D, Vetrivel U, George R, Narayanan J ACS Omega. 2022; 7(19):16536-16546.

PMID: 35601335 PMC: 9118429. DOI: 10.1021/acsomega.2c00701.


LncRNA NR_003923 promotes cell proliferation, migration, fibrosis, and autophagy via the miR-760/miR-215-3p/IL22RA1 axis in human Tenon's capsule fibroblasts.

Zhao Y, Zhang F, Pan Z, Luo H, Liu K, Duan X Cell Death Dis. 2019; 10(8):594.

PMID: 31391457 PMC: 6685939. DOI: 10.1038/s41419-019-1829-1.


Acute Hyperthermia Inhibits TGF-β1-induced Cardiac Fibroblast Activation via Suppression of Akt Signaling.

Narikawa M, Umemura M, Tanaka R, Fujita T, Yokoyama U, Ishigami T Sci Rep. 2018; 8(1):6277.

PMID: 29674727 PMC: 5908876. DOI: 10.1038/s41598-018-24749-6.


Involvement of Rho-associated coiled-coil kinase signaling inhibition in TGF-β1/Smad2, 3 signal transduction .

Feng Z, Zhang X, Zhao J, Ma J Int J Ophthalmol. 2017; 10(12):1805-1811.

PMID: 29259896 PMC: 5733505. DOI: 10.18240/ijo.2017.12.03.


References
1.
Mietz H, Esser J, Welsandt G, Kociok N, Hueber A, Joussen A . Latanoprost stimulates secretion of matrix metalloproteinases in tenon fibroblasts both in vitro and in vivo. Invest Ophthalmol Vis Sci. 2003; 44(12):5182-8. DOI: 10.1167/iovs.02-0462. View

2.
Walter K, Gilbert D . The adverse effect of perioperative brimonidine tartrate 0.2% on flap adherence and enhancement rates in laser in situ keratomileusis patients. Ophthalmology. 2001; 108(8):1434-8. DOI: 10.1016/s0161-6420(01)00627-3. View

3.
WALTERS T . Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996; 41 Suppl 1:S19-26. DOI: 10.1016/s0039-6257(96)82028-5. View

4.
Wu K, Hong S, Wang H . Effects of pilocarpine and other antiglaucoma drugs on cultured human Tenon's fibroblast cells. J Ocul Pharmacol Ther. 1997; 13(1):13-21. DOI: 10.1089/jop.1997.13.13. View

5.
Greenfield D, Liebmann J, Ritch R . Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. J Glaucoma. 1997; 6(4):250-8. View